Wall Street equity research analysts covering Recursion Pharmaceuticals (RXRX) maintain a median 12-month consensus price target hovering around $7.00 per share, with individual high estimates reaching up to $10.00 and conservative low forecasts anchored near $4.00. These projections reflect confidence in its tech-enabled drug discovery platform while factoring in biotech sector clinical trial risks.